High potency silencing by single-stranded boranophosphate siRNA by Hall, Allison H. S. et al.
High potency silencing by single-stranded
boranophosphate siRNA
Allison H. S. Hall
1, Jing Wan
2, April Spesock
1, Zinaida Sergueeva
2,
Barbara Ramsay Shaw
2 and Kenneth A. Alexander
1,3,*
1Department of Molecular Genetics and Microbiology, Box 3020, Duke University Medical Center,
Durham, NC 27710, USA,
2Department of Chemistry, Box 90354, Duke University, Durham,
NC 27708, USA and
3Department of Pediatrics, Section of Pediatric Infectious Diseases,
The University of Chicago, 5841 S. Maryland Ave., MC 6054, Chicago, IL, 60637, USA
Received January 30, 2006; Revised February 15, 2006; Accepted April 17, 2006
ABSTRACT
In RNA interference (RNAi), double-stranded short
interfering RNA (ds-siRNA) inhibits expression
fromcomplementarymRNAs.Recently,itwasdemon-
strated that short, single-stranded antisense RNA
(ss-siRNA) can also induce RNAi. While ss-siRNA
may offer several advantages in both clinical and
research applications, its overall poor activity com-
pared with ds-siRNA has prevented its widespread
use. In contrast to the poor gene silencing activity
of native ss-siRNA, we found that the silencing
activity of boranophosphate-modified ss-siRNA is
comparable with that of unmodified ds-siRNA.
Boranophosphate ss-siRNA has excellent maximum
silencing activity and is highly effective at low con-
centrations. The silencing activity of boranophos-
phate ss-siRNA is also durable, with significant
silencing up to 1 week after transfection. Thus, we
have demonstrated that boranophosphate-modified
ss-siRNA can silence gene expression as well as
native ds-siRNA, suggesting that boranophosphate-
modified ss-siRNAs should be investigated as a
potential new class of therapeutic agents.
INTRODUCTION
RNA interference (RNAi) is a form of post-transcriptional
gene silencing in which double-stranded RNA (dsRNA)
targets complementary mRNAs for destruction [reviewed in
(1–4)]. RNAi occurs in a wide variety of organisms, ranging
from protozoa to mammals. There has been considerable
interest in harnessing the power of RNAi to treat human
diseases such as viral infections (5,6), cancer (7,8) and
sepsis (9). While questions remain about the precise mecha-
nism of RNAi, recent work has provided a clearer under-
standing of the process. In the endogenous RNAi system,
the effector molecule is a double-stranded short interfering
RNA (ds-siRNA)  21 bp in length with 30 dinucleotide
overhangs (10). ds-siRNAs associate with Argonaute family
proteins to form an RNA induced silencing complex
(RISC) (11,12). One of the strands of the ds-siRNA is
removed or destroyed and only a single strand remains in
the mature RISC (13–16). The complex then targets mRNA
complementary to the incorporated strand (13). Thus, it is
the antisense strand of the ds-siRNA that targets a particular
mRNA for destruction.
Several studies have shown that it is possible to bypass the
dsRNA stage by introducing single-stranded antisense RNA
 21 bases long into RNAi-competent cells or cell lysates
(13,17,18). These single-stranded siRNA (ss-siRNA) mole-
cules have several advantages over the standard, ds-siRNA,
particularly in the context of potential clinical applications.
First, as only one RNA strand is needed, the cost and work
of preparation is reduced by half. Single-stranded molecules
may also avoid one of the major obstacles to therapeutic use
of ds-siRNA: unintended side effects. For example, a recent
study showed that both chemically and enzymatically syn-
thesized ds-siRNA species induced interferon expression,
whereas none of the ss-siRNA species provoked a detectable
interferon response (19). Off-target silencing of genes with
similar but non-identical sequences to the sense or antisense
strand is another potential obstacle to the speciﬁcity of siRNA
activity (20). By using a single strand, the risk of off-target
silencing guided by the sense strand is eliminated. Finally,
ss-siRNAs may circumvent the RNAi-suppressing activity
of dsRNA-binding proteins (21,22).
Despite these potential advantages of ss-siRNAs, the
single-stranded molecule has a signiﬁcant shortcoming;
ss-siRNAs do not efﬁciently induce RNAi. ss-siRNA must
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that of ds-siRNA to achieve comparable levels of gene
silencing (13,17,18). The reason for the poor silencing activ-
ity of the single-stranded molecules is not yet known.
To investigate whether the low level of silencing by ss-
siRNAs could be improved, we sought to examine the activ-
ity of ss-siRNAs with the boranophosphate (BP) backbone
modiﬁcation. We have shown previously that BP-modiﬁed
ds-siRNAs are more active for gene silencing than the cor-
responding phosphodiester- or phosphorothioate-backbone
ds-siRNAs (23). In the boranophosphate (BP) linkage
(Figure 1A), a non-bridging phosphodiester oxygen is
replaced with an isoelectronic borane (–BH3
 ) moiety. BP
nucleic acids maintain the ability to base pair with high
speciﬁcity and afﬁnity and BP nucleotides can be readily
incorporated into DNA and RNA molecules by DNA and
RNA polymerases, permitting synthesis of stereoregular bora-
nophosphate oligonucleotides (23–28). The boranophosphate
modiﬁcation appears to be well tolerated in mammalian
systems; BP ds-siRNAs do not induce any appreciable
toxicity in HeLa cells (23). Furthermore, BP DNA dinu-
cleotides are minimally toxic to rodents, and the degradation
product of BP oligonucleotides (borate) is minimally toxic
to humans (23,29,30).
In this work, we demonstrate that partial BP-modiﬁcation
increases the silencing activity of ss-siRNA against green
ﬂuorescent protein in HeLa cells. In our system single-
stranded BP-siRNAs can silence gene expression as well as
native ds-siRNA.
MATERIALS AND METHODS
Synthesis of boranophosphate siRNAs
ss- and dsRNA molecules were synthesized as described pre-
viously (23). Brieﬂy, DNA oligonucleotides were purchased
from Qiagen: T7 promoter primer, 50-TAATACGACTCAC-
TATAG-30; EGFP1 templates: sense, 50-AAGTTCACCTTG-
ATGCCGTTCTATAGTGAGTCGTATTA-30 and antisense,
50-AAGAACGGCATCAAGGTGAACTATAGTGAGTCGTA-
TTA-30; control EGPF1 templates: sense, 50-AAGTTCACCGT-
AGTTCCGTTCTATAGTGAGTCGTATTA-30 and antisense,
50-AAGAACGGAACTACGGTGAACTATAGTGAGTCGT-
ATTA-30; EGFP2 templates: sense, 50-AAGGACTTGAAG-
AAGTCGTGCTATAGTGAGTCGTATTA-30 and antisense,
50-AAGCACGACTTCTTCAAGTCCTATAGTGAGTCGTA-
TTA-30; Control EGFP2 templates: sense, 50-AAGGACTTT-
GAAGAAGCGTGCTATAGTGAGTCGTATTA-30 and
antisense, 50-AAGCACGCTTCTTCAAAGTCCTATAGTG-
AGTCGTATTA-30. ssRNA molecules were synthesized using
T7 RNA polymerase. To create boranophosphate modiﬁed
oligonucleotides, one or more ribonucleoside 50-(a-P-bora-
no)triphosphates were added to the transcription reaction in
place of the corresponding rNTPs. RNAs were then puriﬁed
as single strands using phenol extraction and Microspin
G-50 Micro Columns (Amersham) or PAGE and suspended
in water. To make dsRNA, sense and antisense strands
were ﬁrst annealed and then puriﬁed and concentrated using
Microcon YM-10 centrifugal ﬁlters (Millipore). RNA
concentration was determined by UV absorbance at 260 nm.
Cell culture and transfection
EGFP-TRex HeLa cells, which express enhanced green ﬂuo-
rescent protein (EGFP) under control of a tetracycline respon-
sive promoter, were cultured as described previously (23).
Figure 1. Sequence and structure of interfering RNA. (A) Structure of native
(left) and boranophosphate (Sp isomer, right) ribonucleic acid backbone lin-
kages.(B)NativeandmodifiedsiRNAspecies.Modifiednucleotidesareshown
in boldface. For control siRNAs, the inverted sequence is underlined. Arrows
indicate the linkage opposite the expected target cleavage site. A, antisense
strand;S, sensestrand;b,boranophosphate;n,native; a,adenosine;c,cytidine;
u, uridine; 3, adenosine, cytidine and uridine.
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siRNA using Oligofectamine (Invitrogen) according to the
manufacturer’s instructions with 1.35 ml Oligofectamine per
well of a 24-well plate. The concentration of siRNA in the
cell culture medium ranged from 3.1 to 50 nM, as described
in ﬁgure legends. Twenty-four hours after siRNA transfec-
tion, cells were induced to express EGFP with 1 mg/ml tetra-
cycline. For the EGFP1 control sequence, the six central
nucleotides of the active EGFP1 sequence were inverted.
As the control sequence for EGFP2, we used an siRNA in
which the eight central nucleotides inverted because the
sequence with six inverted nucleotides had an unacceptable
degree of homology to some human mRNAs.
Flow cytometry analysis
Cells were trypsinized and ﬁxed in 1% formaldehyde in
phosphate-buffered saline, 48 h post-transfection. Cells
were analyzed for EGFP expression using a FACScan
(Becton-Dickinson) ﬂow cytometer. Data were processed
using CellQuest software (Becton-Dickinson).
Cellular RNA analysis
Cells were transfected in culture medium at a ﬁnal siRNA
concentration of 12.5 nM. EGFP1 production was induced
with 1 mg/ml tetracycline. Cells were trypsinized and total
cytoplasmic RNA isolated using the RNeasy kit (Qiagen),
22 h after EGFP induction. RNA from each sample (2 mg)
was separated by formaldehyde–agarose gel electrophoresis,
transferred to a positively charged nylon membrane and
crosslinked by UV irradiation. The immobilized RNA was
hybridized with
32P-labeled RNA probes complementary to
the EGFP coding sequence and to human b-actin (to normal-
ize for signal). Hybridization was quantiﬁed using a Molecu-
lar Dynamics phosphorimaging system.
Quantitative RT–PCR
Cells were transfected in culture medium at a ﬁnal siRNA con-
centration of 25 nM or mock transfected with Oligofectamine
(Invitrogen) alone. Cells were trypsinized and total cytoplasmic
RNA isolated using the RNeasy kit (Qiagen), 24 h after trans-
fection. RNA from each sample (1 mg )w a su s e dt om a k e
cDNA using the iScript kit (Bio-Rad). Quantitative PCR was
performed using SYBR Green I (Invitrogen), Platinum Taq
(Invitrogen), 1.5 mM MgCl2 and primers at a concentration
of 0.2 mM. PCR was performed on a Roche Lightcycler and
data were analyzed using Lightcycler software. The following
primers were used: human Ago2, 50-TGGCTGTG-
CCTTGTAAAACGCT-30 and 50-CGCGTCCGAAGGCTGC-
TCTA-30; human GAPDH, 50-CATGTTCGTCATGGGTGTG-
AACCA-30 and 50-AGTGATGGCATGGACTGTGGTCAT-30.
RNase susceptibility analysis
EGFP1 and EGFP2 RNAs (10 pmol) were incubated with
0.5 and 2 ng RNase A (Roche), respectively, in 5 ml RNase
reaction buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA
and 150 mM NaCl) at 37 C for speciﬁed lengths of time.
The RNase reactions were stopped by adding 2 vol of the
gel-loading buffer (10 M urea, 50 mM EDTA, 0.1 bromo-
phenol blue and 0.1% xylene cyanol), and loaded on a
4% agarose gel. After SYBR Gold (Molecular Probes) stain-
ing, the gels were photographed under UV illumination and
analyzed using Fluorescent Image Analytical Software
(Hitachi Software Engineering Co. Ltd).
RESULTS
ds-siRNAs and several species of ss-siRNAs, all targeting
EGFP, were synthesized as described previously (23)
(Figure 1). Brieﬂy, all RNA species were synthesized using
T7 RNA polymerase and puriﬁed as single strands. To create
BP-modiﬁed siRNAs, one or more native ribonucleoside
triphosphate was replaced by its BP counterpart in the
transcription reaction.
Silencing activity of native and BP ss-siRNA
Native and BP ss-siRNAs targeted to EGFP were tested for
silencing activity in HeLa cells that express EGFP under
control of a tetracycline-inducible promoter. For these stud-
ies, cells were transfected with ds- or ss-siRNA, induced to
express EGFP, and then, after 24 h, analyzed by ﬂow cyto-
metry to measure the level of EGFP protein expression.
The ﬂuorescence of cells transfected with siRNA was com-
pared with the ﬂuorescence of mock-transfected cells (treated
with Oligofectamine alone) to determine the percent inhibi-
tion of EGFP expression. To control for non-speciﬁc effects
of the RNA, we tested control sequence ss-siRNAs with the
central 6 or 8 nt inverted (Figure 1B). None of the control
ss-siRNAs silenced EGFP expression (Figure 2).
Initially, EGFP1 sequence ss-siRNAs were tested at a
concentration of 25 nM because this is the concentration at
which silencing by native ds-siRNA approaches a maximum,
thereby allowing comparison of the peak silencing activity of
Figure 2. Position specific effects of boranophosphate modifications on
silencing activity of ss-siRNAs. (A) Percent inhibition of EGFP fluorescence
in cells treated with native or boranophosphate EGFP1 siRNA at 25 nM. To
account for variations in transfection efficiency, the results of each individual
experiment were normalized to results for native siRNA-treated cells in that
experiment. Error bars represent the standard error. (B) Percent inhibition of
EGFP fluorescence in cells treated with native or boranophosphate modified
EGFP2 siRNAat12.5nM. Errorbars representthe standarderror.ds-siRNAis
represented by closed bars. ss-siRNAs are represented by gray bars. A, anti-
sense strand; S, sense strand; b, boranophosphate; n, native; a, adenosine;
c,cytidine;u,uridine;3,adenosine,cytidineanduridine;cont,invertedcontrol
sequence.
Nucleic Acids Research, 2006, Vol. 34, No. 9 2775the different siRNAs. Similar to earlier studies (13,17,18), we
found that native ss-siRNA could inhibit EGFP expression,
but was signiﬁcantly less active than native ds-siRNA
(Figure 2A). When BP-modiﬁed siRNAs were studied, we
found that ss-siRNA with BP-modiﬁed cytidine residues
(Ab
c) silenced EGFP expression with the same efﬁciency
as the unmodiﬁed ds-siRNA. Furthermore, an anti-EGFP
ss-siRNA with modiﬁed adenosine and cytidine residues
was signiﬁcantly more active than native ds-siRNA (99%
versus 70% reduction in EGFP expression, respectively).
While BP modiﬁcation of cytidine and adenosine resi-
dues signiﬁcantly enhanced silencing activity of ss-siRNAs,
ss-siRNAs that included modiﬁed uridines (Ab
u and Ab
3)
were notably less active than unmodiﬁed ss-siRNA. There-
fore, we examined why these species had reduced EGFP
silencing activity. We have demonstrated previously in ds-
siRNAs that a high proportion of BP residues in the center
of the antisense strand reduces siRNA silencing activity
(23). As there are four uridine residues among the central
six nucleotides (those that surround the predicted target
cleavage site, Figure 1B) in the EGFP1 sequence, the
reduced silencing activities of Ab
u and Ab
3 were consistent
with the pattern established previously with ds-siRNAs,
and suggest that modiﬁcation of the central bases of ss-
siRNAs reduces silencing activity in a manner analogous
to the reduction seen with modiﬁcation of the central
bases of double-stranded BP-siRNAs.
While we suspected that extensive modiﬁcation of central
nucleotides caused the reduction in siRNA silencing, the loss
of activity in ss-siRNAs with modiﬁed uridines could also
have been due to modiﬁcation of the two residues on the
30 end, or simply due to the presence of modiﬁed uridines.
To further examine the relationship between modiﬁcation
sites and ss-siRNA activity, a different anti-EGFP sequence
(EGFP2) was tested. This sequence has two uridines at the
30 end; however, none of the six central nucleotides are
uridines. Instead, there are four adenosines in this region
(Figure 1B). Once again, the native ss-siRNA had a much
lower level of silencing activity than native ds-siRNA
(Figure 2B). However, BP-modiﬁcation of the uridine
residues (all peripheral) caused a dramatic increase in
ss-siRNA activity, almost restoring it to the level of ds-
siRNA. In contrast, when adenosine residues were modiﬁed
in the EGFP2 molecule (resulting in modiﬁcation of 3 of
the central 6 nt), activity remained at a low level. These
results demonstrate that BP-modiﬁed uridine residues and
30 overhangs are compatible with ss-siRNA activity and
provide additional support for the hypothesis that multiple
central BP modiﬁcations interfere with efﬁcient silencing.
The overall pattern of increased activity with peripheral
modiﬁcation and reduced activity with central modiﬁcation
was consistent for both anti-EGFP sequences. However, in
contrast to the results for EGFP1 ss-siRNAs, increasing the
degree of peripheral BP modiﬁcation in EGFP2 ss-siRNAs
caused a slight decrease in silencing activity (Figure 2B,
Ab
u and Ab
cu).
Dose response of native and BP ss-siRNA
We determined silencing dose response curves for several
anti-EGFP1 siRNAs (Figure 3). As we had observed when
a single siRNA concentration was used, the double-stranded
native A
nS
n siRNA exhibited moderate silencing activity.
A
nS
n induced an  80% reduction in EGFP ﬂuorescence at
50 nM siRNA and had half maximal silencing activity in
the range of 2 nM. In contrast, A
n silences EGFP expression
only modestly, inducing only  60% silencing at 50 mM with
half maximal silencing at  15 nM. When BP cytidine resi-
dues are introduced to the EGFP1 ss-siRNA, its activity
improves such that the dose response curve of Ab
c is almost
identical to that of A
nS
n. When modiﬁed cytidine and aden-
osine residues are used, silencing activity of the ss-siRNA
becomes highly active; Ab
ac induces close to 100% EGFP
silencing at 25 nM, with half-maximal silencing induced at
 1 nM siRNA.
Kinetics of silencing by native and BP ss-siRNA
Next, we examined the effect of BP modiﬁcation on
ss-siRNA silencing over time. HeLa cells were transfected
with siRNA, induced to express EGFP after 5 h or after 1,
3, 5 or 7 days and ﬁxed 24 h after induction. To assess the
duration of silencing relative to each interfering RNA’s activ-
ity, the level of silencing after 1 day was normalized to 100.
While the activity of all RNA species starts to decline after
3 days, the activity of native ss-siRNA (A
n) declines much
more quickly than that of native ds-siRNA (A
nS
n)o rB P
ss-siRNAs (Ab
c,A b
ac) (Figure 4). It should be noted that the
raw data reveal that, consistent with our other results, native
ss-siRNA was signiﬁcantly less active than native ds-siRNA
and that modiﬁed ss-siRNAs were as active (Ab
c) or more
active (Ab
ac) than native ds-siRNA at all times tested (data
not shown). Notably, the raw data also reveal that Ab
ac still
reduced EGFP expression by  50% 1 week after trans-
fection. Finally, while other investigators have reported that
ss-siRNA achieves maximum silencing more quickly than
ds-siRNA (18), we did not observe such a pattern.
Figure 3. Effect of boranophosphate modification on silencing dose response
of ss-siRNAs. Silencing of EGFP fluorescence in cells treated with native or
boranophosphate EGFP1 siRNA over a range of concentrations. (A) The
activity of each siRNA at 50 nM is normalized to an arbitrary value of 100.
(B) Raw dose response data. Error bars represent the standard error. A
nS
n is
represented by closed circles, A
n by open circles, Ab
c by closed triangles and
Ab
ac byopentriangles.A,antisensestrand;S, sensestrand;b,boranophosphate;
n, native; a, adenosine; c, cytidine.
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siRNAs inhibit protein expression primarily by inducing
cleavage of target mRNA. However, it has also been shown
that some RNA species, known as miRNAs, can silence
genes by inhibiting translation of their targets (31). Previous
work suggests that the presence of a base mismatch or a bulge
when the siRNA pairs with its target can cause it to function
through the miRNA pathway rather than by the RNAi mecha-
nism (32). Because miRNAs have been shown to function as
single strands (33), we investigated whether BP ss-siRNAs
might act by inhibiting translation of target mRNA. The
effects of BP ss-siRNA and native ds-siRNA on EGFP mRNA
levels were examined by northern blot and were normalized
to b-actin expression. Similar to ds-siRNA, BP-modiﬁed
ss-siRNA caused a reduction in the level of EGFP mRNA
(Figure 5A). To compare the relative change in protein and
mRNA levels, samples of the cells used for northern analysis
were analyzed by ﬂow cytometry. If the BP ss-siRNA inhib-
ited translation in addition to reducing mRNA levels, it
should cause a relatively greater protein inhibition than
mRNA inhibition, compared with unmodiﬁed ds-siRNA.
Instead, for both native ds-siRNA and BP ss-siRNA, the
percent inhibition of protein expression closely matches the
percent inhibition of mRNA expression (Figure 5B). Further-
more, the ratios of the reductions in protein levels to the
reductions in mRNA levels are the same for BP ss-siRNA
and native ds-siRNA. We therefore conclude that modiﬁed
ss-siRNAs inhibit protein expression primarily by reducing
EGFP mRNA levels, rather than by inhibiting translation.
BP ss-siRNA activity requires Argonaute2 expression
Having determined that BP ss-siRNA silence protein
expression by mRNA cleavage, we further examined the
process of silencing by these molecules. Previous work has
suggested that native ss-siRNA act through the RISC to
induce RNAi (13,17,18). However, in all of these studies,
the concentrations of ss-siRNA required to achieve gene
silencing comparable with that induced by ds-siRNA were
6- to 100-fold higher. Therefore, it is important to determine
whether the highly efﬁcient silencing observed with BP
ss-siRNA is due to RISC-related activity or to engagement
of a different gene silencing mechanism, such as induction
of degradation by a double-stranded RNase (34). To deter-
mine the RISC-dependence of BP ssRNA silencing, we
examined the effect of siRNAs that have been shown to
knock-down expression of Argonaute2 (Ago2), a key compo-
nent of the RISC (35). For these studies, EGFP-HeLa cells
were transfected with Ago2 siRNA or with control, non-
silencing siRNA. The cells were transfected with native
ds-siRNA (which is known to interact with the RISC) or
BP ss-siRNA targeted to EGFP, 24 h later. Cells were
induced to express EGFP 24 h after the second transfection
and analyzed by ﬂow cytometry 24 h after induction. It has
been demonstrated previously that when RISC is disrupted
by knocking-down Ago2 expression, silencing by ds-siRNA
is eliminated (35). If BP ss-siRNA acts through a RISC-
dependent process, its silencing activity should be also
dramatically reduced when Ago2 is silenced.
Figure 4. Effect of BP modification on the duration of ss-siRNA silencing.
Percent inhibition of EGFP fluorescence over time in cells treated with native
ds-siRNA or native/BP ss-siRNA (all EGFP1 sequence) at 25 nM. To examine
the relative change in activity over time, the degree of silencing at 1 day after
transfection for each siRNA was set at an arbitrary value of 100. Error bars
represent the standard error. A
nS
n is represented by closed circles, A
n by open
circles, Ab
c by closed triangles and Ab
ac by open triangles. A, antisense strand;
S, sense strand; b, boranophosphate; n, native; a, adenosine; c, cytidine.
Figure 5. Effect of single-stranded BP siRNA on EGFP mRNA and protein
levels.(A)NorthernblotoftotalcytoplasmicRNAfrommocktransfectedcells
(M) or cells transfected with EGFP1 siRNA. (B) Percent reduction in mRNA
(closedbars)andprotein(graybars)levelsasdeterminedbynorthernandFACS
analysis. Samples of cells from the same population were used for both ana-
lyses.EGFPmRNAlevelswerenormalizedtob-actinexpression.A,antisense
strand;S, sensestrand;n, native;b,boranophosphate;a,adenosine;c,cytidine;
cont, EGFP1 control sequence.
Nucleic Acids Research, 2006, Vol. 34, No. 9 2777The siRNA targeted to Ago2 caused a notable reduction
in Ago2 expression as measured by quantitative RT–PCR
(Figure 6A). We found that when Ago2 expression was sup-
pressed, the ability of native ds-siRNA to silence EGFP
expression was reduced dramatically, compared with cells
initially transfected with control siRNA (Figure 6B). The
silencing activity of BP ss-siRNA was abrogated to a similar
extent by Ago2 silencing, indicating that BP ss-siRNA acts
primarily through a RISC-dependent process (Figure 6B).
To ensure that inhibiting Ago2 expression does not, by itself,
affect EGFP expression, we also examined cells transfected
with Ago2 siRNA, followed by control siRNA. The Ago2
siRNA did not appreciably affect EGFP expression; mean
ﬂuorescence for mock transfected and Ago2 transfected
cells were 537.1 and 536.1, respectively (in arbitrary
units). The combination of the northern blot and the Ago2
knock-down data suggests that BP ss-siRNA acts primarily
through the standard RNAi pathway used by ds-siRNA.
BP-modification has variable effects on ss-siRNA
nuclease resistance
Having demonstrated that the BP modiﬁcation dramatically
improves the silencing activity of ss-siRNAs, we sought to
examine the reason for this change in activity. Given the sus-
ceptibility of ssRNA to RNases and the enhanced nuclease
stability of BP-modiﬁed dsRNA (23), we initially speculated
that the enhanced silencing activity of BP ss-siRNAs was
at least partially due to their greater resistance to RNase
degradation. To test this hypothesis, we examined the suscep-
tibility of native and BP ss-siRNAs to degradation by RNase
A. As expected, unmodiﬁed ss-siRNA was very susceptible
to nuclease digestion while ds-siRNA was relatively resistant
to degradation (Figure 7). Boranophosphate modiﬁcation did
enhance nuclease resistance of some ss-siRNA species. How-
ever, BP modiﬁcation did not result in a consistent improve-
ment in nuclease stability, nor did resistance to RNase
degradation correlate with greater silencing activity. Notably,
the most active siRNA we tested, the EGFP1 ss-siRNA with
modiﬁed adenosine and cytosine residues, was degraded at
essentially the same rate as the native ss-siRNA. This result
suggests that nuclease resistance may not be the sole reason
for the enhanced silencing activity of BP ss-siRNAs.
DISCUSSION
ssRNA can efficiently induce RNAi
While testing the silencing activity of native and boranophos-
phate modiﬁed ss- and ds-siRNAs, we discovered that BP
ss-siRNA can be a highly effective gene silencing tool. As
seen in several previous studies (13,17,18), we found that
the gene silencing activity of unmodiﬁed ss-siRNA was
substantially less than that of ds-siRNA. In contrast, we
found that the most effective BP-modiﬁed ss-siRNA species
(EGFP1 Ab
ac, with modiﬁed adenosine and cytidine residues)
Figure 6. Silencing by boranophosphate ss-siRNA is Ago2-dependent. (A)
Cells we mock-transfected with Oligofectamine alone (mock) or transfected
with control ds-siRNA (control) or ds-siRNA targeted to Ago2 (Ago2). Ago2
mRNA levels were measured by quantitative RT–PCR and normalized to
GAPDH mRNA levels. (B) Cells were transfected with control ds-siRNA
(closed bars) or ds-siRNA targeted to Ago2 (gray bars). Twenty-four hours
later, cells were retransfected with control ds-siRNA, EGFP1 native ds-siRNA
(A
nS
n) or EGFP1 BP ss-siRNA (Ab
ac). EGFP fluorescence was measured by
flow cytometry. Data were normalized with silencing by anti-EGPF siRNAs
after initial transfection with control siRNA set at an arbitrary value of 100.
Error bars represent standard error.
Figure 7. NucleasestabilityofnativeandboranophosphateRNA.ss-ssRNAswereincubatedwithRNaseAforthetimesindicatedandthenassessedfordegradation
by agarose gel electrophoresis. b, boranophosphate; n, native; A, adenosine; C, cytidine; U, uridine; 3, adenosine, cytidine and uridine.
2778 Nucleic Acids Research, 2006, Vol. 34, No. 9is even more active than native ds-siRNA, implying that
ss-siRNA can be efﬁciently incorporated into the RISC
(Figures 2 and 3). The maximum activity of Ab
ac is also
greater than that of any BP-modiﬁed ds-siRNA that we
have examined (data not shown) (23). To our knowledge,
this is the ﬁrst demonstration that the silencing activity of
ssRNA can match or exceed that of dsRNA. Also, given
our ﬁndings that BP ss-siRNA silencing is due to a reduction
in mRNA levels and is Argonaute2-dependent, it seems likely
that BP ss-siRNA acts through the standard RNAi pathway.
Structure-activity relationships in BP ss-siRNA
We found that position effects of BP modiﬁcations followed
the same general rule we discerned when testing BP-modiﬁed
dsRNA (23): peripheral BP modiﬁcation is well tolerated,
while central modiﬁcations cause a signiﬁcant loss of activ-
ity. However, the magnitude of the beneﬁt of peripheral BP
modiﬁcation was greater when applied to single-stranded
molecules. At 25 nM, peripheral modiﬁcation of ss-siRNA
caused up to a 2.4-fold increase in silencing activity
(Figure 2, Ab
ac), compared with a maximum increase in
ds-siRNA activity of 1.3-fold (23).
Because peripheral modiﬁcations dramatically increase
ss-siRNA silencing activity, we initially hypothesized that
the positive attributes conferred by central modiﬁcations
would offset their inhibitory effects, such that even central
modiﬁcations would enhance activity. Instead, ss-siRNA spe-
cies with central modiﬁcations have activity levels that are as
low as or lower than those of native ss-siRNA (Figure 2).
Apparently, the unfavorable effects of central modiﬁcation
are still signiﬁcant in single-stranded molecules. The poor
activity of centrally modiﬁed ds-siRNA and ss-siRNA may
reﬂect a disruption of the enzymatic activity of the RISC,
which cleaves the target directly across from the center of
the interfering RNA (36). Previous studies have demonstrated
that central sequence mismatches or ribose modiﬁcations
inhibit ds-siRNA activity (36,37), although the regions that
are sensitive to such changes appears to be more extensive
than the area that is sensitive to BP modiﬁcation.
Mechanisms of enhanced activity in
boranophosphate ss-siRNA
We initially hypothesized that BP-modiﬁed ss-siRNAs would
be more nuclease resistant that native ss-siRNA and that this
would be a major reason for their enhanced silencing activity.
However, we found that BP modiﬁcation did not consistently
result in greater resistance to RNase A digestion for the seq-
uences tested here. Indeed, the BP ss-siRNA species with the
greatest silencing activity (EGFP1 Ab
ac) was degraded at
essentially the same rate as native ss-siRNA (Figure 7). It
is still possible that BP modiﬁcation could confer greater sta-
bility within the cell or in the culture medium; RNase A resis-
tance may not directly correlate with resistance to other
nucleases. However, the absence of an observable increase
in RNAse stability with BP modiﬁcation suggests that the
enhanced activity of BP ss-siRNAs may not be solely due
to improved nuclease resistance. This hypothesis is supported
by other work showing that modiﬁcations that confer nucle-
ase resistance do not necessarily enhance the activity of
ds- or ss-siRNAs (37,38).
Instead, we suspect that BP ss-siRNAs have other advanta-
geous properties that confer efﬁcient silencing activity.
Borane substitution of a non-bridging oxygen results in
changes in size, charge, polarity and stereochemistry (39).
It can be imagined that the presence of a borane group instead
of oxygen in the phosphate backbone of RNA would change
their interaction with other molecules, e.g. mRNA target
and RISC protein components. Indeed, we have found
recently that BP modiﬁcation raises the melting temperature
of siRNAs, suggesting that a modiﬁed siRNA might have a
greater afﬁnity for the target mRNA than a native siRNA
(40). Another characteristic of BP siRNA that may enhance
its silencing activity is its tendency to make an A-form
helix (40). The results of several different studies suggest
that efﬁcient cleavage of the target RNA requires the
A-form structure between the guide strand of the ds-siRNA
and the target (37,41,42). Investigation of the interactions
between BP ss-siRNA and RISC should facilitate mechanistic
understanding of RNAi and may suggest generally applicable
strategies for enhancing siRNA activity.
Therapeutic potential of boranophosphate ss-siRNAs
Our examination of silencing by boranophosphate-modiﬁed
ss-siRNA suggests that BP ss-siRNA could have signiﬁcant
therapeutic potential. The high maximum activity, potency
at low concentrations and duration of silencing by EGFP1
Ab
ac suggest that relatively low and infrequent dosing of BP
ss-siRNA could be effective, even in rapidly dividing cells.
Indeed, by accounting for dilution by cell division and
comparing the activity over time to dose response curves, it
appears that essentially all of the decline in activity can be
accounted for by this dilution. Therefore, we expect that
silencing would last even longer in non-dividing cells or
when the siRNA blocks cell growth (7).
In addition to its excellent silencing activity, BP ss-siRNA
has advantages unique to ssRNA: simpliﬁed synthesis and
no risk of off-target silencing by the sense strand. Further-
more, the smaller size and reduced negative charge of
ss-siRNA may facilitate delivery into cells. We also believe
that ssRNA is less likely to induce an interferon response
than dsRNA. Most examinations of interferon induction by
siRNAs have shown that ss-siRNAs do not provoke an inter-
feron response (19). However, a recent publication reported
that ssRNA synthesized by phage polymerases (the method
used here) can induce interferon expression due to the pres-
ence of 50 triphosphate groups (43). In the context of potential
clinical applications, this should not pose a signiﬁcant prob-
lem because the terminal phosphates can be easily removed
by calf intestinal alkaline phosphatase treatment (43).
Because control sequence siRNAs (also synthesized by T7
polymerase) did not show any silencing activity (Figure 2),
we do not believe that our analysis of silencing activity was
affected by the presence of 50 triphosphate groups on the
siRNAs we tested.
The use of single-stranded molecules may be particularly
desirable in speciﬁc situations. For example, BP ss-siRNAs
may permit the use of sequences whose sense strand sequence
would be nearly complementary to other (off-target) human
genes. In addition, the ability to use single-stranded mole-
cules should enhance silencing by sequences that would
Nucleic Acids Research, 2006, Vol. 34, No. 9 2779otherwise have poor activity due to incorporation of the inac-
tive sense strand into the RISC [it should be noted that other
strategies to favor incorporation of the active strand have also
been developed (44)]. This relaxation of sequence require-
ments is likely to be especially important when there are rela-
tively few potential sequences, such as when the target is a
particular splice variant or mRNA with a speciﬁc point muta-
tion. ss-siRNAs are also likely to be useful in treating viral
infections because many human viruses express dsRNA-
binding proteins, presumably to evade the host cell interferon
response (21,22).
CONCLUSION
We have shown that boranophosphate modiﬁed ss-siRNA
efﬁciently induces silencing at high and low concentrations
and for extended periods of time. This ﬁnding is signiﬁcant,
because it demonstrates that, when appropriately modiﬁed,
ss-siRNA can induce RNAi at least as effectively as ds-
siRNA. It also introduces a new category of molecules for
potential use as RNAi-based therapeutics.
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